Cutaneous melanoma is an aggressive tumor responsible for 90% of mortality related to skin
cancer. In the recent years, the discovery of driving mutations in melanoma has led to better …

We live in an unprecedented time in oncology. We have accumulated samples and cases in
cohorts larger and more complex than ever before. New technologies are available for …

Abstract BRAF, NRAS and TERT mutations occur in more than 2/3 of melanomas. Its
detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for …

Melanoma heterogeneity is a hurdle in metastatic disease management. Although the
advent of targeted therapy has significantly improved patient outcomes, the occurrence of …

Background Forty to fifty percent of patients with locally advanced squamous cell carcinoma
of the head and neck (LA SCCHN) relapse despite multimodal treatment. Circulating tumor …

Simple Summary Uveal melanoma (UM) is a rare cancer, with no effective standard systemic
therapy in the metastatic setting. Over 95% of UM harbor activating driver mutations that can …

Circulating tumor DNA (ctDNA) is the cornerstone of liquid biopsy diagnostics, revealing
clinically relevant genomic aberrations from blood of cancer patients. Genomic analysis of …

Opinion statement Because the recent success of novel therapeutic approaches has
dramatically changed the clinical management of melanoma, less invasive and repeatable …

Malignant melanoma has shown an increasing incidence during the last two decades,
exhibiting a large spectrum of locations and clinicopathological characteristics. Although …

Simple Summary Although multiple actionable genes have been identified in melanoma, 38–
42% of patients are still not druggable based on current research. In our study, DNA-NGS …